DSF/Cu enhances the sensitivity of BRAF-mutant thyroid cancer cells to PLX4032 by inhibiting HER3 and AKT in a ROS-dependent manner, thereby alleviating the feedback activation of the MAPK/ERK and PI3K/AKT pathways. The gene discussed is AKT1; the disease is thyroid gland carcinoma.